Amgen reported a $1.33 billion profit in its fourth quarter, driven by a double‑digit volume boost that lifted revenue. The biotech giant also benefited from lower net unrealized losses on equity investments, tightening its earnings profile and reinforcing investor confidence in the face of a competitive market and rising R&D costs.

Volume gains stem from stronger sales of Amgen’s flagship drugs, including EYLEA and PROZAC, as well as new indications for its oncology portfolio. Compared to the third quarter, revenue rose 8%, while the company’s market share in the eye‑care segment edged higher, signaling a solid foothold against rivals in 2024.

With earnings above expectations, Amgen is poised to revisit its guidance for 2025, potentially raising revenue forecasts and expanding its pipeline. Analysts will watch for upcoming regulatory approvals and any strategic acquisitions that could further diversify its product mix. Investors should monitor quarterly updates for signs of sustained growth today.